2.42
  Price6.61%   +0.1500
(After Hours: 2.40 -0.0200 -0.83%)
Calls Options of OCGN for 2022-07-15 (Expired in 4 days)
Strike Price Change % Change Volume
favorite 0.50 2.10 0.00 0.00% 0
favorite 1.00 1.58 0.00 0.00% 0
favorite 1.50 0.75 0.00 0.00% 0
favorite 2.00 0.33 -0.02 -5.71% 16
favorite 2.50 0.11 0.04 +57.14% 752
favorite 3.00 0.03 0.00 0.00% 213
favorite 3.50 0.03 0.00 0.00% 70
favorite 4.00 0.02 0.01 +100.00% 6
favorite 4.50 0.00 0.00 0.00% 0
favorite 5.00 0.01 0.00 0.00% 10
Puts Options of OCGN for 2022-07-15 (Expired in 4 days)
Strike Price Change % Change Volume
favorite
0.50
0.00 0.00 0.00% 0
favorite
1.00
0.00 0.00 0.00% 0
favorite
1.50
0.01 0.00 0.00% 0
favorite
2.00
0.04 -0.03 -42.86% 27
favorite
2.50
0.25 0.00 0.00% 12
favorite
3.00
0.64 -0.20 -23.81% 13
favorite
3.50
0.00 0.00 0.00% 0
favorite
4.00
0.00 0.00 0.00% 0
favorite
4.50
0.00 0.00 0.00% 0
favorite
5.00
2.49 0.00 0.00% 0
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Cap:    |  Volume (24h):